Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Phase 3 Interventional

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

NCT04520750
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
PTX-022
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Phoenix, Arizona • Palo Alto, California • Fridley, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT00004182
View directory record Official record
Conditions
Breast Cancer
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
2
States / cities
Stanford, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography

NCT04348123
View directory record Official record
Conditions
Breast Cancer
Interventions
Survey, Education Session
Other · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 7:10 AM EDT
Withdrawn Phase 2 Interventional

Proton Accelerated Partial Breast Irradiation

NCT03940248
View directory record Official record
Conditions
Breast Cancer
Interventions
Proton Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
50 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Not applicable Interventional Results available

Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer

NCT02076074
View directory record Official record
Conditions
Breast Neoplasms
Interventions
accelerated partial breast irradiation
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D3 for Aromatase Inhibitor Induced Arthralgias

NCT00867217
View directory record Official record
Conditions
Breast Cancer
Interventions
High Dose Vitamin D, Placebo, Standard Dose Vitamin D3, Letrozole 2.5mg
Dietary Supplement · Drug
Lead sponsor
Qamar Khan
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Westwood, Kansas • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 31, 2026, 7:10 AM EDT
Completed No phase listed Observational Results available

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

NCT01896050
View directory record Official record
Conditions
Breast Cancer, Arthralgia, Obesity
Interventions
anastrozole, letrozole, exemestane, Tamoxifen
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

NCT00899574
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Imiquimod
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2Phase 3 Interventional

TempTouch IR Thermometry & Diabetic Patient Self-Care

NCT00289497
View directory record Official record
Conditions
Diabetic Polyneuropathy, Diabetic Foot Ulcer, Diabetes, Foot Infection
Interventions
TempTouch®
Device
Lead sponsor
Diabetica Solutions Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
3
States / cities
New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2006 · Synced Oct 31, 2026, 7:10 AM EDT
Recruiting Phase 3 Interventional

Tissue Repair Gel in Venous Leg Ulcers (US)

NCT06707090
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wounds, Venous Insufficiency of Leg, Non-healing Wound
Interventions
TR987 0.1% gel + Standard of Care, Standard of care
Drug · Other
Lead sponsor
TR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Castro Valley, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 31, 2026, 7:10 AM EDT
Terminated Phase 4 Interventional Results available

Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

NCT01825655
View directory record Official record
Conditions
Pruritus
Interventions
Cetirizine, Placebo or sugar pill
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 31, 2026, 7:10 AM EDT
Terminated Phase 2Phase 3 Interventional

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

NCT02191748
View directory record Official record
Conditions
Vitiligo
Interventions
Needling, Triamcinolone
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 31, 2026, 7:10 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

NCT00426985
View directory record Official record
Conditions
Tendonitis, Bursitis
Interventions
Ketoprofen Topical Patch 20%, Placebo
Drug · Other
Lead sponsor
Alkemira SA
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 7:10 AM EDT
Completed No phase listed Observational

Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention

NCT06168825
View directory record Official record
Conditions
Cancer, Breast Cancer, Brain Cancer, Central Nervous System Cancer, Colorectal Cancer, Esophageal Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Melanoma, Blood Cancer, Lung Cancer, Acceptance and Commitment Therapy, Mind-Body Therapies, Psychosocial Intervention
Interventions
Mind Over Matter (MOM)
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

NCT01679197
View directory record Official record
Conditions
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

NCT03135782
View directory record Official record
Conditions
Breast Carcinoma, Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Prostate Carcinoma, Tobacco Use
Interventions
Communication Skills Training, Medical Chart Review, Questionnaire Administration, Tobacco Cessation Counseling
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

NCT00796978
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment
Biological · Other · Procedure
Lead sponsor
Cynthia Owusu, MD
Other
Eligibility
60 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
11
States / cities
Miami, Florida • Winston-Salem, North Carolina • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea

NCT01614743
View directory record Official record
Conditions
Rosacea
Interventions
IncobotulinumtoxinA, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

NCT03845517
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Fullerton, California • La Palma, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

NCT05695950
View directory record Official record
Conditions
Dermatomyositis
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 7:10 AM EDT
Not listed Phase 1Phase 2 Interventional

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Low Strength, IDP-118 High Strength
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Santa Rosa, California • Clinton Township, Michigan • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 31, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT02798120
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 31, 2026, 7:10 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab to Treat Active Lupus Nephritis

NCT04868838
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daratumumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 7:10 AM EDT